Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1F2ix1g
Cap comentari:
Publica un comentari a l'entrada